Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The antidepressant escitalopram likely caused hair loss in a patient.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This review highlights brimonidine’s potential as a dermatological agent, noting its ability to improve rosacea-related facial redness and its effectiveness in various other skin conditions due to its vasoconstrictive and anti-inflammatory actions, with minimal systemic absorption and a favorable safety profile for long-term use.

This study found that bupropion SR may improve symptoms in female trichotillomania patients who did not respond to SSRIs, with benefits maintained through a 16-month follow-up.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This letter discusses a case of iododerma in pregnancy linked to iodinated multivitamin use, but reports no new clinical findings.

This case report describes a woman who developed trichotillomania during long COVID and saw improvement in symptoms with the SSRI escitalopram.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that duloxetine and escitalopram exhibited broad-spectrum antimicrobial activity, while buspirone had selective effects, and finasteride disrupted yeast virulence traits, suggesting these drugs could be repurposed as antimicrobial therapies.

A man developed an allergic skin reaction after using brimonidine for rosacea.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study found that fluoxetine did not demonstrate short-term efficacy in treating trichotillomania in a placebo-controlled, double-blind crossover setting.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

Pill splitting increased generic finasteride sales but didn't affect branded finasteride sales.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.